TD Cowen raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $39 from $35 and keeps a Buy rating on the shares. The firm noted the company is expected to release topline Ph3 PBO-controlled PWS data of ACP-101 (intranasal carbetocin) in early Q4 and after adding the Ph3 PWS program to their pNPV, they raised their target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $39 from $36 at UBS
- Acadia Pharmaceuticals names Katcheves Chief Business and Strategy Officer
- Acadia Pharmaceuticals price target raised to $36 from $32 at UBS
- ACADIA Pharmaceuticals: Strong Growth and Undervalued Pipeline Support Buy Rating
- ACADIA Pharmaceuticals Reports Strong Q2 2025 Earnings